Business
Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S
Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S Copenhagen, 10 December 2025 Company Announcement no. 15 Pharma Equity Group A/S ("PEG") today announces that the company has signed a Letter of Intent regarding the acquisition of the entire share capital or a majority stake in Otiom A/S. The transaction marks the first concrete step in PEG’s expanded strategy to become a leading consolidator within Life Science, spa
About this update from Pharma Equity Group A/s Class A
[{"type":"image","alt":"Pharma Equity Group A/S","displaySize":"","headline":null,"caption":"Pharma Equity Group A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PTz7GpCf_hKeFTaw0Xo7Fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/83879c7411aab943b7350e2e06a6fb7c","width":300,"height":34}},"lazy":false},{"type":"text","content":"Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S","length":133,"tagName":"p"},{"type":"text","content":"Copenhagen, 10 December 2025","length":28,"tagName":"p"},{"type":"text","content":"Company Announcement no. 15","length":27,"tagName":"p"},{"type":"text","content":"Pharma Equity Group A/S ("PEG") today announces that the company has signed a Letter of Intent regarding the acquisition of the entire share capital or a majority stake in Otiom A/S. The transaction marks the first concrete step in PEG’s expanded strategy to become a leading consolidator within Life Science, spanning Pharma, MedTech, and other health related technologies.","length":384,"tagName":"p"},{"type":"text","content":"Strategic Rationale: From Vision to Action","length":42,"tagName":"p"},{"type":"text","content":"In line with the Company's newly published strategy, PEG focuses on identifying and scaling Nordic innovation companies that solve significant unmet medical needs.","length":167,"tagName":"p"},{"type":"text","content":"Otiom A/S fits strongly into this strategic framework. The company has developed a patented localization technology specifically designed for people with dementia – an area with significant growth and with immense human and societal needs. By integrating Otiom into PEG, we demonstrate the ability to expand the company's portfolio from pure drug development (Reponex Pharmaceuticals) to also include commercializable MedTech.","length":430,"tagName":"p"},{"type":"text","content":""With Otiom, PEG delivers the first concrete proof of the our ability to execute on the Company's new strategy. We promised the market to diversify PEG's portfolio with assets that have a shorter path to market and commer...